The Fountain Health 4-Phase Ketamine Therapy Framework™

A Clinically Informed Model Integrating Neuroplastic Science with Structured Psychiatric Care

Executive Summary

This document proposes a structured four-phase clinical framework for ketamine-assisted psychiatric care. The model integrates emerging neuroplasticityThe formation of synapses between neurons. research with applied outpatientTreatment provided without an overnight stay. Fountain Health's IV therapies are outpatient by design. psychiatric practice to improve durability of response and care sequencing.

Core Thesis

The therapeutic impact of sub-anesthetic ketamine derives not solely from the acute dissociative experience, but from a transient neuroplastic state that follows administration. This window of enhanced plasticity may be optimized through structured preparation, guided integrationThe process of making sense of and applying insights after a therapeutic experience such as ketamine therapy., and behavioral consolidation.

The Four Phases

• Preparation
• Activation
• Integration
• Consolidation

Clinical Implication

Ketamine therapy is best conceptualized as a sequenced care pathway rather than an isolated pharmacologic intervention. Outcomes may depend as much on post-session engagement as on the infusion itself.

Intended Audience

Psychiatrists, psychotherapists, integrative mental health clinicians, program designers, and health journalists seeking a structured framework grounded in contemporary neurobiology.

Introduction

Over the past decade, ketamine has transitioned from anesthetic agent to rapid-acting psychiatric intervention for treatment-resistant depressionDepression that persists despite adequate trials of antidepressant treatment., traumaA deeply distressing experience that leaves lasting psychological impact.-related conditions, and affective dysregulation. Its entry into mainstream psychiatric practice has been unusually rapid.

Early clinical enthusiasm often emphasized the dissociative or psychedelic aspects of the experience. More recent literature, however, increasingly frames ketamine through a mechanistic lens centered on glutamatergic modulation and synaptic plasticity. NMDA receptorA glutamate receptor involved in synaptic signaling, learning, and memory. antagonism leads to downstream AMPA receptorA glutamate receptor involved in fast excitatory neurotransmission in the brain. activation, BDNFA neurotrophic factor involved in neuron survival and plasticity related to learning and memory. release, and mTOR-mediated synaptogenesisThe formation of synapses between neurons.. These cascades suggest that ketamine may induce a transient window of enhanced neuroplasticity.

Yet in day-to-day clinical work, the infusion itself rarely tells the whole story. Durable psychiatric change does not appear to unfold through pharmacology alone. Long-term outcomes seem influenced by how biological activation is integrated with structured psychological engagement and behavioral reinforcement.

This document proposes a clinically derived four-phase model for structuring ketamine therapy within a broader psychiatric care architecture.

Why the Infusion Alone Is Not the Treatment

Sub-anesthetic ketamine induces rapid neurobiological change. Symptom reduction may occur within hours. In some cases, patients describe a perceptible shift the same day. However, the neuroplastic window extends beyond the acute session into the 24–72 hours that follow.

When ketamine is delivered as an isolated pharmacologic intervention, improvement may be transient. When embedded within preparation, structured integrationThe process of making sense of and applying insights after a therapeutic experience such as ketamine therapy., and behavioral consolidation, durability may increase.

Ketamine should therefore be understood not as a standalone event, but as a biologically mediated inflection point within a sequenced therapeutic process.

The Four Phases of the Ketamine Therapy Journey

Phase 1 — Preparation (Mind | Body | Existential Orientation)

Preparation includes psychiatric assessment, medical screening, lifestyle stabilization, and psychoeducation.

Biologically, sleep regulation, metabolic balance, inflammation reduction, and physical activity prime neural systems for plasticity engagement.

Psychologically, therapeutic alliance, expectation-setting, and intention clarification establish cognitive readiness.

Within the existential domain, patients are invited to clarify values, personal meaning, and desired change trajectory.

In clinical observation, patients entering treatment with stabilized biological rhythms and structured preparation often demonstrate more coherent integrationThe process of making sense of and applying insights after a therapeutic experience such as ketamine therapy. following activation.

Phase 2 — Activation (Biological Induction of Plasticity)

Ketamine administration initiates a glutamatergic cascade via NMDA antagonism and AMPA activation, stimulating BDNFA neurotrophic factor involved in neuron survival and plasticity related to learning and memory. release and mTOR-mediated synaptogenesisThe formation of synapses between neurons..

The session is delivered within a monitored clinical environment emphasizing physiological safety and psychological containment.

During activation, cognitive rigidity may temporarily soften. Fear-based circuits and entrenched rumination patterns may become more malleable.

The activation phase is biologically necessary but not sufficient for durable change.

Phase 3 — Integration (Cognitive, Behavioral, and Existential Structuring)

The post-session plasticity window represents a critical therapeutic opportunity.

Structured psychotherapy during this period may support narrative restructuring, cognitive reframing, traumaA deeply distressing experience that leaves lasting psychological impact. processing, and behavioral activation.

Lifestyle reinforcement — including sleep optimization, physical activity, nutritional stability, and social engagement — may help consolidate adaptive circuitry.

Patients who actively engage in integrationThe process of making sense of and applying insights after a therapeutic experience such as ketamine therapy. often demonstrate greater durability of symptom improvement compared to infusion-only models.

Without structured integrationThe process of making sense of and applying insights after a therapeutic experience such as ketamine therapy., the neuroplastic window may close without sustained behavioral modification.

Phase 4 — Consolidation (Durability and Resilience)

Consolidation focuses on stabilizing adaptive neural pathways through repetition and reinforcement.

Maintenance sessions, behavioral consistency, community engagement, and identity-level shifts may support long-term resilienceThe ability to adapt and recover from stress, trauma, or illness..

The clinical objective transitions from acute symptom relief to functional stability and relapseA return to substance use after a period of improvement. threshold elevation.

Repeated integrationThe process of making sense of and applying insights after a therapeutic experience such as ketamine therapy. cycles may strengthen synaptic density and network resilienceThe ability to adapt and recover from stress, trauma, or illness. over time.

Table 1. The Four-Phase Clinical Sequencing Model for Ketamine-Assisted Psychiatry

Clinical Origin of the Framework

The model did not arise from theory first, but from clinical patterns observed repeatedly across patient trajectories Variability in durability appeared associated not only with dosing or frequency, but with the degree of structured preparation and post-session engagement.

Patients who relied solely on pharmacologic intervention frequently experienced transient benefit. Those who engaged in structured integrationThe process of making sense of and applying insights after a therapeutic experience such as ketamine therapy. and behavioral reinforcement demonstrated more sustained outcomes.

In response, care sequencing was formalized into the four-phase model presented here.

The framework is therefore clinically derived and aligned with emerging mechanistic literature.

Scientific Basis

The model aligns with contemporary findings regarding:

• NMDA receptor antagonism
• AMPA receptor activation
• Brain-derived neurotrophic factor (BDNF) signaling
• mTOR-mediated synaptogenesis
• Functional connectivity changes in the prefrontal cortex, hippocampus, and anterior cingulate cortex

These mechanisms support the hypothesis that ketamine induces a temporary state of enhanced neural plasticity.

Structured therapeutic engagement during this window may influence durability.

Limitations and Scope

This framework is conceptual and hypothesis-generating. It has not yet been validated through controlled comparative trials evaluating structured multi-phase sequencing versus infusion-alone models.

Individual response to ketamine remains heterogeneous and influenced by psychiatric diagnosis, traumaA deeply distressing experience that leaves lasting psychological impact. history, metabolic healthHow efficiently your body manages blood sugar, cholesterol, and energy balance. A strong predictor of long-term wellness., psychosocial environment, and therapeutic alliance.

The model is intended as a structured clinical orientation rather than a prescriptive protocol.

Further empirical research is warranted to evaluate outcome differentials across care sequencing strategies.

Conclusion

Rapid-acting neuroplastic interventions challenge traditional symptom-suppression paradigms in psychiatry.

Ketamine therapy, when delivered within a structured care architecture, may function as a biological catalyst embedded within psychological and behavioral sequencing.

The Fountain Health 4-Phase Ketamine Therapy Framework™ proposes an integrated approach aligning neurobiology with structured therapeutic engagement.

Modern psychiatry increasingly requires models that bridge mechanism and lived patient experience.

References

Piazza, M. K., Kavalali, E. T., & Monteggia, L. M. (2024). Ketamine-induced synaptic plasticity operates independently of long-term potentiation. Neuropsychopharmacology, 49, 1758–1766. https://www.nature.com/articles/s41386-024-01895-2

Miller, C. B., Lopes, B., & McCurdy, A. (2025). The collective lie in ketamine therapy: A call to realign clinical practice with neurobiology. Frontiers in Psychiatry, 16. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1610335/full

Yun, J. Y., et al. (2024). Neural correlates of treatment response to ketamine for treatment-resistant depressionDepression that persists despite adequate trials of antidepressant treatment.: A systematic review of MRI studies. Journal of Affective Disorders, 320, 123–135. https://www.sciencedirect.com/science/article/pii/S0165178124003779

Li, Q., et al. (2025). Research progress on the mechanism of ketamine in improving hippocampal neuroplasticityThe formation of synapses between neurons.. Frontiers in Neuroscience. https://pmc.ncbi.nlm.nih.gov/articles/PMC12350550/

Mikellides, G. (2025). Ketamine and esketamineAn FDA-approved esketamine nasal spray with specific labeled indications and safety requirements. in psychiatry: A comparative review emphasizing neuroplasticityThe formation of synapses between neurons. and clinical applications. Psychoactives, 4(3), 20. https://www.mdpi.com/2813-1851/4/3/20

Version 1.0 | 2026
Fountain Health NYC